However, we did not find any significant impacts of different patient gender (female vs. male), age population (children vs. adults) and tumor locations (temporal vs. nontemporal) on either CD34 expression (see Table 1) or BRAF mutation (see Table 3), or even surgical prognosis (see Table 4), in GG with epilepsy in our cohort. The gene discussed is BRAF; the disease is neoplasm.